For enrollment information involving the following trials, please contact one of the research staff members on the "Meet the Team" page.
Phase III randomized double-blind study of adjuvant Axitinib versus Placebo in kidney cancer patients at high risk of cancer recurrence.
• Newly-diagnosed kidney cancer treated with nephrectomy
• Undefferentaited histopathology, sarcoma, collecting duct carcinoma, or lymphoma
Sponsor: SFJ Pharma Ltd. on behalf of Pfizer
Principal Investigator: Dr. Viraj Master
Kidney tissue and specimen bank at Emory University and affiliated medical centers.
Any patient undergoing kidney cancer screening or kidney cancer treatment.
Eligible Treatment Centers:
• Emory University Hospital
• Following surgical removal, all tissue will be processed by the Department of Pathology for routine standard histopathological examination. For the tissue bank, a small portion of the tissue will be used for research testing.
Principal Investigator: Dr. John Petros